Please login to the form below

Not currently logged in
Email:
Password:

Lilly’s Strattera wins new adult ADHD licence in UK

On course for wider EU approval for adults yet to receive treatment

Lilly Strattera atomoxetine ADHD

Adults in the UK with attention deficit hyperactivity disorder (ADHD) who were not prescribed medicine as a child will now have access to Lilly's Strattera after it was approved by the country's regulator.

The Medicines and Healthcare Products Regulatory Agency (MHRA) granted authorisation to expand the indication of Strattera (atomoxetine) to initiate treatment of ADHD in adults, where pre-existing symptoms during childhood can be confirmed by a third-party.

This adds to current indications covering its use to treat children and adolescents, as well as adults whose symptoms persist and who had been prescribed the drug when younger.

The approval will be used as a basis for Lilly to gain EU-wide approval trough the European Medicines Agency (EMA) as part of the region's mutual recognition process.

It is the first time a drug has gained ADHD approval in the EU for a specific adult use, and marks an important step for adults diagnosed with ADHD who were undiagnosed or misdiagnosed for other common mental health disorders during their childhood.

“This can occur because the signs and symptoms of ADHD can overlap with those of other common mental health disorders,” said Professor Philip Asherson, Professor of Clinical and Molecular Psychiatry at King's College London and president of the UK Adult ADHD Network (UKAAN), “and because primary and secondary care mental health services may lack the training and experience required to accurately identify the disorder."

He added: “In some cases this can lead to patients being treated for a personality or mood disorder when the main problem is ADHD.”

According to Prof Asherson, this is especially significant as about two third of children and adolescent with ADHD continue to have symptoms into adulthood.

In the UK alone, 1.7 million adults are estimated to have ADHD, with the condition able to impact family, work and social relationships.

Uptake of Strattera in adults is likely to be influenced by guidance from National Institute for Health and Care Excellence (NICE) and the British Association of Psychopharmacology, both of which state adults with the condition have access to drug treatment.

Strattera's new licence is backed by results from clinical trials that demonstrate it can achieve significant improvements in ADHD symptoms and quality of life outcomes.

4th June 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics